The thesis

DocuSign provides electronic signature software. The company is in the midst of an AI Buildout market force. Conviction is currently dormant with a composite score of 0/100. Despite this, the company has raised guidance and expects ARR growth to accelerate in fiscal year 2027, with IAM ARR representing 18-19% of total ARR by the end of Q4, backed by 9.4% YoY revenue growth and a gross margin of 79.49%.

Why now

Management's confident tone in the last earnings and the expectation of accelerating ARR growth in fiscal year 2027 makes this a timely investment consideration. The AI Buildout is expected to continue until 2030, according to some analysts.

What to watch

The company's ARR growth acceleration in fiscal year 2027 and the proportion of IAM ARR to total ARR by the end of Q4 are key indicators to watch. The company's ability to maintain its gross margin above 79% is also crucial.

Key risks

The high P/E ratio of 39.1x poses a valuation risk. Execution risk is also present as the company needs to meet its ARR growth expectations. Competitive risk is another concern as the e-signature market may become increasingly crowded.

Theme exposure

Upcoming catalysts